Twist Bioscience Corp

For the period ended Sep 30, 2025. Filed Nov 17, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Nov 17, 2025

TWST$132.13-2.4%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Stockholders’ Equity

Common stock · Additional paid-in capital · Accumulated other comprehensive income / (loss) · Accumulated deficit · Total stockholders' equity
(In thousands) · Shares · Amount
Balances as of September 30, 2022	56,523	$—		$1,619,644		$(1,843)		$(828,416)	$789,385
Vesting of restricted stock units	648	$—		$—		$—		$—	$—
Issuance of shares under the employee stock purchase plan	217	—	3,937		—	—	3,937
Exercise of stock options	118	—	1,379		—	—	1,379
Business acquisition	277	—	5,860		—	—	5,860
Stock-based compensation expense	—	—	30,821		—	—	30,821
Other comprehensive income	—	—	—		1,087		1,087
Repurchase of common stock for income tax withholdings	(226)	—	(4,419)		—	—	(4,419)
Net loss	—	—	—		—	(204,618)	(204,618)
Balances as of September 30, 2023	57,557	$—		$1,657,222		$(756)		$(1,033,034)	$623,432
Impact of ASU 2016-13 adoption	—	$—		$—		$—		$(148)	$(148)
Vesting of restricted stock units	896	—	—		—	—	—
Issuance of shares under the employee stock purchase plan	177	—	3,765		—	—	3,765
Exercise of stock options	384	—	7,100		—	—	7,100
Stock-based compensation expense	—	—	51,007		—	—	51,007
Other comprehensive loss	—	—	—		234	—	234
Repurchase of common stock for income tax withholdings	(137)	—	(3,975)		—	—	(3,975)
Net loss	—	—	—		—	(208,726)	(208,726)
Balances as of September 30, 2024	58,877	$—		$1,715,119		$(522)		$(1,241,908)	$472,689
Restricted common stock canceled	(137)	$—		$—		$—		$—	$—
Vesting of restricted stock units	1,260	—	—		—	—	—
Issuance of shares under the employee stock purchase plan	144	—	4,213		—	—	4,213
Exercise of stock options	488	—	9,343		—	—	9,343
Stock-based compensation expense	—	—	64,504		—	—	64,504
Other comprehensive loss	—	—	—		(105)	—	(105)
Repurchase of common stock for income tax withholdings	—	—	(16)		—	—	(16)
Net loss	—	—	—		—	(77,670)	(77,670)
Balances as of September 30, 2025	60,632	$—		$1,793,163		$(627)		$(1,319,578)	$472,958

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.